SCN9A and lung carcinoma: Nav1.7 has been shown to be the prominent Nav subtype in the H460 lung cancer and SH-SY5Y neuroblastoma cell lines [31,40] and we decided to investigate channel activity in these two cell lines with a specific Nav1.7 antagonist and a more general inhibitor.